- Home
- TKLF vs BCLI Comparison
TKLF vs BCLI Comparison
Compare TKLF & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- BCLI
- Stock Information
- Founded
- TKLF 2006
- BCLI 2000
- Country
- TKLF Japan
- BCLI United States
- Employees
- TKLF N/A
- BCLI N/A
- Industry
- TKLF Other Specialty Stores
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TKLF Consumer Discretionary
- BCLI Health Care
- Exchange
- TKLF Nasdaq
- BCLI Nasdaq
- Market Cap
- TKLF 15.7M
- BCLI 9.9M
- IPO Year
- TKLF 2022
- BCLI N/A
- Fundamental
- Price
- TKLF $3.90
- BCLI $1.73
- Analyst Decision
- TKLF
- BCLI Strong Buy
- Analyst Count
- TKLF 0
- BCLI 1
- Target Price
- TKLF N/A
- BCLI $30.00
- AVG Volume (30 Days)
- TKLF 19.4K
- BCLI 41.1K
- Earning Date
- TKLF 12-18-2024
- BCLI 03-31-2025
- Dividend Yield
- TKLF N/A
- BCLI N/A
- EPS Growth
- TKLF N/A
- BCLI N/A
- EPS
- TKLF 1.70
- BCLI N/A
- Revenue
- TKLF $219,520,631.00
- BCLI N/A
- Revenue This Year
- TKLF N/A
- BCLI N/A
- Revenue Next Year
- TKLF N/A
- BCLI N/A
- P/E Ratio
- TKLF $2.29
- BCLI N/A
- Revenue Growth
- TKLF 32.02
- BCLI N/A
- 52 Week Low
- TKLF $2.00
- BCLI $1.05
- 52 Week High
- TKLF $8.53
- BCLI $11.85
- Technical
- Relative Strength Index (RSI)
- TKLF 58.90
- BCLI 40.62
- Support Level
- TKLF $3.52
- BCLI $1.69
- Resistance Level
- TKLF $4.12
- BCLI $1.93
- Average True Range (ATR)
- TKLF 0.20
- BCLI 0.11
- MACD
- TKLF 0.02
- BCLI -0.00
- Stochastic Oscillator
- TKLF 69.44
- BCLI 16.67
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores; Online Stores and Services; and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from China followed by Japan and other overseas markets.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.